| Case Name | Date Filed | Judge | Drug | Patent No(s). |
|---|---|---|---|---|
| Indivior Inc. v. Alvogen Pine Brook LLC, 18-5285 (D.N.J.) | Apr. 3, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,931,305 |
| Indivior Inc. v. Dr. Redy’s Labs., Inc., 18-5288 (D.N.J.) | Apr. 3, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,931,305 |
| Indivior Inc. v. Par Pharm., Inc., 18-5293 (D.N.J.) | Apr. 3, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,931,305 |
| Indivior Inc. v. Teva Pharms. USA, Inc., 18-5300 (D.N.J.) | Apr. 3, 2018 | Hon. Kevin McNulty | Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) | 9,931,305 |
| Egalet US, Inc. v. Teva Pharms. USA, Inc., 18-0505 (D. Del.) | Apr. 4, 2018 | Hon. Gregory M. Sleet | Arymo® (morphine sulfate extended-release tablets) | 9,044,402 |
| Eli Lilly and Co. v. Apotex, Inc., 18-1037 (S.D. Ind.) | Apr. 4, 2018 | Hon. William T. Lawrence | Forteo® (teriparatide for injection) | 7,517,334 |
| Eli Lilly and Co. v. Apotex, Inc., 18-0518 (D. Del.) | Apr. 5, 2018 | Hon. Leonard P. Stark | Forteo® (teriparatide for injection) | 7,517,334 |
| Senju Pharm. Co., Ltd. v. Amneal Pharms. LLC, 18-5571 (D.N.J.) | Apr. 5, 2018 | Hon. Brian R. Martinotti | Prolensa® (bromfenac ophthalmic solution) | 8,129,431 8,669,290 8,754,131 8,871,813 8,927,606 9,144,609 9,517,220 9,561,277 |
| Mylan Pharms. Inc. v. Bristol-Myers Squibb Co., IPR2018-00892 (PTAB) | Apr. 5, 2018 | N/A | Eliquis® (apixaban tablets) | 9,326,945 |
| iCeutica Pty Ltd. v. Teva Pharms. USA, Inc., 18-0525 (D. Del.) | Apr. 6, 2018 | Vacant Judgeship (2017) | Vivlodex® (meloxicam capsules) | 9,526,734 9,649,318 9,808,468 |
| Dr. Reddy’s Labs. Inc. v. Pozen Inc., IPR2018-00894 (PTAB) | Apr. 6, 2018 | N/A | Vimovo® (esomeprazole magnesium / naproxen delayed-release tablets) | 9,220,698 |
| Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 18-5752 (D.N.J.) | Apr. 9, 2018 | Hon. Jose L. Linares | Narcan® (naloxone HCl nasal spray) | 9,480,644 9,707,226 |
| Eli Lilly and Co. v. Sunshine Lake Pharma Co., Ltd., 18-5765 (D.N.J.) | Apr. 9, 2018 | Hon. William H. Walls | Cialis® (tadalafil tablets) | 6,943,166 |
| Mitsubishi Tanabe Pharma Corp. v. Prinston Pharm. Inc., 18-6112 (D.N.J.) | Apr. 11, 2018 | Hon. Freda L. Wolfson | Invokana® (canagliflozin tablets) | 7,943,788 |
| Dr. Reddy’s Labs., Inc. v. GlaxoSmithKline LLC, 18-0548 (D. Del.) | Apr. 12, 2018 | Hon. Leonard P. Stark | Lamictal XR® (lamotrigine extended-release tablets) | 8,637,512 9,144,547 |
| Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 18-6378 (D.N.J.) | Apr. 12, 2018 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 6,315,720 6,561,977 6,755,784 8,315,886 8,626,531 |
| Shire Development LLC v. Impax Labs., Inc., 18-0549 (D. Del.) | Apr. 13, 2018 | Hon. Richard G. Andrews | Mydayis® (dextroamphetamine saccharate / amphetamine aspartate monohydrate / dextroamphetamine sulfate / amphetamine sulfate extended-release capsules) | 6,913,768 8,846,100 9,173,857 |
| IBSA Institut Biochimique, S.A. v. Teva Pharms. USA, Inc., 18-0555 (D. Del.) | Apr. 13, 2018 | Hon. Leonard P. Stark | Tirosint® (levothyroxine sodium capsules) | 7,691,411 7,723,390 |
| UCB, Inc. v. Apotex Inc., 18-60846 (S.D. Fla.) | Apr. 17, 2018 | Hon. Marcia G. Cooke | Xyzal Allergy 24HR® (levocetirizine dihydrochloride solution) | 8,633,194 |
| Acerta Pharma B.V. v. Pharmacyclics LLC, 18-581 (D. Del.) | Apr. 18, 2018 | Vacant Judgeship (2017) | Calquence® (acalabrutinib capsules) Imbruvica® (ibrutinib capsules) |
7,459,554 |
| Biogen Int’l GmbH v. Banner Life Sciences LLC, 18-0582 (D. Del.) | Apr. 18, 2018 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) Bafiertam® (dimethyl fumarate delayed-release capsules) |
7,320,999 8,399,514 |
| UCB, Inc. v. Apotex Inc., 18-3404 (S.D.N.Y.) | Apr. 18, 2018 | Hon. J. Paul Oetken | Xyzal Allergy 24HR® (levocetirizine dihydrochloride solution) | 8,633,194 |
| Onyx Therapeutics, Inc. v. Cipla Ltd., 18-0598 (D. Del.) | Apr. 20, 2018 | Hon. Leonard P. Stark | Kyprolis® (carfilzomib for injection) | 7,417,042 7,737,112 8,207,125 8,207,126 8,207,127 |
| iCeutica Pty Ltd. v. Novitium Pharma LLC, 18-0599 (D. Del.) | Apr. 20, 2018 | Vacant Judgeship (2017) | Vivlodex® (meloxicam capsules) | 9,526,734 9,649,318 9,808,468 |
| Amneal Pharms. LLC v. Alkermes Pharma Ireland Ltd., IPR2018-00943 (PTAB) | Apr. 20, 2018 | N/A | Vivitrol® (naltrexone extended-release suspension) | 7,919,499 |
| Eisai Co., Ltd. v. Bionpharma Inc., 18-0618 (D. Del.) | Apr. 24, 2018 | Hon. Leonard P. Stark | Banzel® (rufinamide tablets) | 6,740,669 7,750,028 |
| Jazz Pharms., Inc. v. Lupin Ltd., 18-8267 (D.N.J.) | Apr. 24, 2018 | Hon. Esther Salas | Xyrem® (sodium oxybate oral solution) | 9,486,426 |
| Biogen Int’l GmbH v. Zydus Pharms. (USA) Inc., 18-0623 (D. Del.) | Apr. 25, 2018 | Hon. Leonard P. Stark | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 |
| Biogen Int’l GmbH v. Zydus Pharms. (USA) Inc., 18-8323 (D.N.J.) | Apr. 25, 2018 | Hon. Brian R. Martinotti | Tecfidera® (dimethyl fumarate delayed-release capsules) | 6,509,376 |
| Celgene Corp. v. Zydus Pharms. (USA) Inc., 18-8519 (D.N.J.) | Apr. 27, 2018 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,977,357 8,193,219 8,431,598 |
| Sun Pharm. Indus. Ltd. v. Saptalis Pharms., LLC, 18-0648 (D. Del.) | Apr. 30, 2018 | Vacant Judgeship (2017) | Riomet® (metformin HCl oral solution) | 6,890,957 |
| Vanda Pharms. Inc. v. Teva Pharms. USA, Inc., 18-0651 (D. Del.) | Apr. 30, 2018 | Vacant Judgeship (2017) | Hetlioz® (tasimelteon capsules) | RE46,604 9,060,995 9,539,234 9,549,913 9,730,910 9,855,241 |
| Sun Pharm. Indus. Ltd. v. Saptalis Pharms., LLC, 18-2545 (E.D.N.Y.) | Apr. 30, 2018 | Hon. Joan M. Azrack | Riomet® (metformin HCl oral solution) | 6,890,957 |
| AstraZeneca AB v. Zydus Pharms. (USA) Inc., 18-0664 (D. Del.) | 1-May-18 | Hon. Richard G. Andrews | Farxiga® (dapagliflozin tablets) | 6,414,126 6,515,117 |
| H. Lundbeck A/S v. Sigmapharm Labs., LLC, 18-0671 (D. Del.) | 3-May-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 7,144,884 8,476,279 8,722,684 8,969,355 9,227,946 9,861,630 |
| H. Lundbeck A/S v. Torrent Pharms. Ltd., 18-0672 (D. Del.) | 3-May-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 9,861,630 |
| AstraZeneca AB v. Zydus Pharms. (USA) Inc., 18-8778 (D.N.J.) | 3-May-18 | Hon. Freda L. Wolfson | Farxiga® (dapagliflozin tablets) | 6,414,126 6,515,117 |
| H. Lundbeck A/S v. Sigmapharm Labs., LLC, 18-1880 (E.D. Pa.) | 4-May-18 | Hon. Juan R. Sanchez | Trintellix® (vortioxetine hydrobromide tablets) | 7,144,884 8,476,279 8,722,684 8,969,355 9,227,946 9,861,630 |
| Vanda Pharms. Inc. v. Apotex Inc., 18-689 (D. Del.) | 7-May-18 | Vacant Judgeship (2017) | Hetlioz® (tasimelteon capsules) | RE46,604 9,060,995 9,539,234 9,549,913 9,730,910 9,855,241 |
| Vanda Pharms. Inc. v. MSN Pharms. Inc., 18-690 (D. Del.) | 7-May-18 | Vacant Judgeship (2017) | Hetlioz® (tasimelteon capsules) | RE46,604 9,060,995 9,539,234 9,549,913 9,730,910 9,855,241 |
| Noven Pharms., Inc. v. Amneal Pharms. LLC, 18-0699 (D. Del.) | 8-May-18 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) | 9,730,900 9,724,310 9,833,419 |
| Celgene Corp. v. Cipla Ltd., 18-8964 (D.N.J.) | 8-May-18 | Hon. Susan D. Wigenton | Revlimid® (lenalidomide capsules) | 7,977,357 8,193,219 8,431,598 |
| Sun Pharm. Indus., Inc. v. Perrigo Co., 18-0703 (D. Del.) | 9-May-18 | Vacant Judgeship (2017) | Ultravate® (halobetasol propionate lotion) | 8,962,028 |
| Sun Pharm. Indus., Inc. v. Perrigo Co., 18-0530 (W.D. Mich.) | 10-May-18 | Hon. Janet T. Neff | Ultravate® (halobetasol propionate lotion) | 8,962,028 |
| Adamas Pharma, LLC v. Sandoz Inc., 18-9032 (D.N.J.) | 10-May-18 | Hon. Brian R. Martinotti | Gocovri® (amantadine HCl extended-release capsules) | 8,389,578 8,796,337 8,889,740 8,895,614 8,895,615 8,895,616 8,895,617 8,895,618 8,741,343 9,867,791 9,867,792 9,867,793 9,877,933 |
| Eli Lilly and Co. v. Amneal Pharms. LLC, 18-9071 (D.N.J.) | 10-May-18 | Hon. William H. Walls | Cialis® (tadalafil tablets) | 6,943,166 |
| H. Lundbeck A/S v. Cipla Ltd., 18-0753 (D. Del.) | 17-May-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 9,861,630 |
| Astellas Pharma Inc. v. Eugia Pharma Specialties Ltd., 18-0757 (D. Del.) | 17-May-18 | Hon. Gregory M. Sleet | Xtandi® (enzalutamide capsules) | 7,709,517 8,183,274 9,126,941 |
| Noven Pharms., Inc. v. Actavis Labs. UT, Inc., 18-0758 (D. Del.) | 17-May-18 | Hon. Leonard P. Stark | Minivelle® (estradiol transdermal system) | 9,730,900 9,724,310 9,833,419 |
| Impax Labs., Inc. v. Actavis Labs FL, Inc., 18-9347 (D.N.J.) | 17-May-18 | Hon. Stanley R. Chesler | Rytary® (levodopa / carbidopa extended-release capsules) | 9,901,640 |
| Gilead Sciences, Inc. v. Aurobindo Pharma Ltd., 18-0765 (D. Del.) | 18-May-18 | Hon. Joseph F. Bataillon | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) | 6,642,245 6,703,396 |
| Mylan Technologies, Inc. v. Noven Pharms., Inc., IPR2018-01119 (PTAB) | 18-May-18 | N/A | Minivelle® (estradiol transdermal system) | 9,833,419 |
| Bial – Portela & Ca S.A. v. SPH Shanghai Zhongxi Pharm. Co., Ltd., 18-0775 (D. Del.) | 21-May-18 | Vacant Judgeship (2017) | Aptiom® (eslicarbazepine acetate tablets) | 5,753,646 8,372,431 9,206,135 9,566,244 9,643,929 9,750,747 9,763,954 |
| H. Lundbeck A/S v. Lupin Ltd., 18-0777 (D. Del.) | 21-May-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 9,861,630 |
| Promius Pharma LLC v. Perrigo UK Finco Ltd Partnership, 18-0219 (E.D. Tex.) | 22-May-18 | Hon. Robert W. Schroeder, III | Sernivo® (betamethasone dipropionate spray) | 9,364,485 9,433,630 9,439,911 9,655,907 9,775,851 9,877,974 |
| Promius Pharma LLC v. Perrigo UK Finco Ltd Partnership, 18-1415 (D. Minn.) | 23-May-18 | Hon. Susan R. Nelson | Sernivo® (betamethasone dipropionate spray) | 9,439,911 9,655,907 9,775,851 9,877,974 |
| Promius Pharma LLC v. Taro Pharms., Inc, 18-4576 (S.D.N.Y.) | 23-May-18 | Hon. Alvin K. Hellerstein | Sernivo® (betamethasone dipropionate spray) | 9,364,485 9,433,630 9,439,911 9,655,907 9,775,851 9,877,974 |
| Janssen Products, L.P. v. Dr. Reddy’s Labs., Inc., 18-9655 (D.N.J.) | 24-May-18 | Hon. William H. Walls | Prezista® (darunavir tablets) | 8,518,987 7,126,015 7,595,408 |
| Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH, IPR2018-01143 (PTAB) | 24-May-18 | N/A | Xarelto® (rivaroxaban tablets) | 9,539,218 |
| Pfizer Inc. v. Apotex, Inc., 18-0795 (D. Del.) | 25-May-18 | Hon. Leonard P. Stark | Inlyta® (axitinib tablets) | 8,791,140 |
| Shire Development LLC v. SpecGx LLC, 18-0800 (D. Del.) | 25-May-18 | Hon. Richard G. Andrews | Mydayis® (dextroamphetamine saccharate / amphetamine aspartate monohydrate / dextroamphetamine sulfate / amphetamine sulfate extended-release capsules) | 6,913,768 8,846,100 9,173,857 |
| Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 18-9880 (D.N.J.) | 30-May-18 | Hon. Jose L. Linares | Narcan® (naloxone HCl nasal spray) | 9,775,838 |
| Par Pharm., Inc. v. Eagle Pharms. Inc., 18-0823 (D. Del.) | 31-May-18 | Vacant Judgeship (2017) | Vasostrict® (vasopressin injection) | 9,375,478 9,687,526 9,744,209 9,744,239 9,750,785 9,937,223 |
| Fresenius Kabi USA, LLC v. Eurohealth Int’l Sarl, 18-0835 (D. Del.) | 1-Jun-18 | Hon. Leonard P. Stark | Dilaudid® (hydromorphone HCl for injection) | 9,731,082 9,248,229 |
| Cipla Ltd. v. Eli Lilly and Co., 18-1671 (S.D. Ind.) | 1-Jun-18 | Hon. Jane Magnus-Stinson | Cialis® (tadalafil tablets) | 6,821,975 7,182,958 |
| Astellas Pharma Inc. v. Cipla Ltd., 18-0844 (D. Del.) | 5-Jun-18 | Hon. Richard G. Andrews | VESIcare® (solifenacin succinate tablets) | 6,017,927 |
| Cipla Ltd. v. Alcon Research, Ltd., IPR2018-01020 (PTAB) | 5-Jun-18 | N/A | Pazeo® (olopatadine HCl ophthalmic solution) | 8,791,154 |
| Cipla Ltd. v. Alcon Research, Ltd., IPR2018-01021 (PTAB) | 5-Jun-18 | N/A | Pazeo® (olopatadine HCl ophthalmic solution) | 9,533,053 |
| H. Lundbeck A/S v. MSN Labs. Private Ltd., 18-0853 (D. Del.) | 7-Jun-18 | Hon. Leonard P. Stark | Trintellix® (vortioxetine hydrobromide tablets) | 9,861,630 |
| Purdue Pharma L.P. v. Ascent Pharms., Inc., 18-0855 (D. Del.) | 7-Jun-18 | Hon. Richard G. Andrews | OxyContin® (oxycodone HCl extended-release tablets) | 9,060,976 9,073,933 9,522,919 9,147,533 9,861,582 8,309,060 9,675,610 |
| Teijin Ltd. v. MSN Labs. Private Ltd., 18-0881 (D. Del.) | 14-Jun-18 | Vacant Judgeship (2017) | Uloric® (febuxostat tablets) | 7,361,676 8,372,872 9,107,912 |
| Celgene Corp. v. Synthon Pharms. Inc., 18-10775 (D.N.J.) | 19-Jun-18 | Hon. Esther Salas | Pomalyst® (pomalidomide capsules) | 8,198,262 8,673,939 8,735,428 8,828,427 |
| Celgene Corp. v. Synthon Pharms. Inc., 18-0540 (M.D.N.C.) | 21-Jun-18 | Hon. Loretta C. Biggs | Pomalyst® (pomalidomide capsules) | 8,198,262 8,673,939 8,735,428 8,828,427 |
| Astellas Pharma Inc. v. Aurobindo Pharma Ltd., 18-0932 (D. Del.) | 25-Jun-18 | Hon. Richard G. Andrews | VESIcare® (solifenacin succinate tablets) | 6,017,927 |
| Celgene Corp. v. Sandoz Inc., 18-11026 (D.N.J.) | 26-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Celgene Corp. v. Mankind Pharma Ltd., 18-11081 (D.N.J.) | 26-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 7,893,101 |
| Gilead Sciences, Inc. v. Strides Pharma, Inc., 18-11134 (D.N.J.) | 27-Jun-18 | Hon. Michael A. Shipp | Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) | 6,642,245 6,703,396 8,592,397 8,716,264 9,457,036 9,744,181 |
| Celgene Corp. v. Torrent Pharms. Ltd., 18-11156 (D.N.J.) | 27-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 7,893,101 9,872,854 |
| Celgene Corp. v. Shilpa Medicare Ltd., 18-11157 (D.N.J.) | 27-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 7,893,101 9,872,854 |
| Celgene Corp. v. Glenmark Pharms. Ltd., 18-11158 (D.N.J.) | 27-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Amgen Inc. v. Accord Healthcare, Inc., 18-0956 (D. Del.) | 28-Jun-18 | Unassigned Judge | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| Celgene Corp. v. Macleods Pharms. Ltd., 18-11212 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 |
| Celgene Corp. v. MSN Labs. Private Ltd., 18-11213 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 |
| Celgene Corp. v. Teva Pharms. USA, Inc., 18-11215 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Celgene Corp. v. Prinston Pharm. Inc., 18-11216 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 |
| Celgene Corp. v. Emcure Pharms. Ltd., 18-11218 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 9,872,854 |
| Celgene Corp. v. Aurobindo Pharma Ltd., 18-11219 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Celgene Corp. v. Annora Pharma Private Ltd., 18-11220 (D.N.J.) | 28-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 7,427,638 9,872,854 |
| Otsuka Pharm. Co., Ltd. v. Alkem Labs. Ltd., 18-0972 (D. Del.) | 29-Jun-18 | Hon. Richard G. Andrews | Samsca® (tolvaptan tablets) | 8,501,730 |
| Amgen Inc. v. Accord Healthcare, Inc., 18-0575 (M.D.N.C.) | 29-Jun-18 | Hon. William L. Osteen, Jr. | Sensipar® (cinacalcet HCl tablets) | 9,375,405 |
| AstraZeneca Pharms. LP v. Apotex Inc., 18-11238 (D.N.J.) | 29-Jun-18 | Hon. Renee Marie Bumb | Faslodex® (fulvestrant for injection) | 6,774,122 7,456,160 8,329,680 8,466,139 |
| Celgene Corp. v. Cipla Ltd., 18-11262 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,208,516 7,427,638 7,659,302 7,893,101 8,455,536 8,802,717 9,018,243 9,872,854 |
| Celgene Corp. v. Alkem Labs. Ltd., 18-11265 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,427,638 7,659,302 7,893,101 8,455,536 9,018,243 |
| Celgene Corp. v. Zydus Pharms. USA, Inc., 18-11267 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,427,638 7,659,302 7,893,101 8,455,536 9,018,243 |
| Celgene Corp. v. Unichem Labs., Ltd., 18-11268 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,427,638 7,659,302 7,893,101 8,455,536 9,018,243 |
| Celgene Corp. v. Dr. Reddy’s Labs., Inc., 18-11269 (D.N.J.) | 29-Jun-18 | Hon. Michael A. Shipp | Otezla® (apremilast tablets) | 6,962,940 7,427,638 7,659,302 7,893,101 8,455,536 9,018,243 |
Related Attorneys
Partner
